Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study
March 22, 2022 - Strategic options to be explored following Phase 3 study
Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study
November 29, 2021 - 1,000 subjects enrolled in RESUME-1
Neurana Pharmaceuticals to Present at Piper Sandler Healthcare Conference
November 24, 2021 - Presentation at Piper Sandler 33rd Annual Healthcare Conference
Neurana Pharmaceuticals Announces Publication in Pain Management
July 7, 2021 - Neurana Pharmaceuticals Announces Publication in Pain Management
Neurana Pharmaceuticals to Present at American Society of Interventional Pain Physicians Meeting
June 25, 2021 - Presentation of CNS Effects Study at ASIPP
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
June 7, 2021 - 50% of subjects enrolled in RESUME-1
Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors
June 1, 2021 - Georgia Erbez and Liz Cermak to join BOD
Neurana Pharmaceuticals to Present at 21st Annual Pain Therapeutics Conference
May 11, 2021 - Presentation at Pain Therapeutics Conference
Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study
December 21, 2020 - First patient enrolled in RESUME-1
Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study
December 8, 2020 - Positive top-line results from Phase 1 CNS Effects Study
Neurana Pharmaceuticals to Present at Piper Sandler 32nd Annual Healthcare Conference
November 24, 2020 - Presentation at Piper Sandler 32nd Annual Healthcare Conference
Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
November 23, 2020 - Publication in the Journal of Pain Research
Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek® National Conference
September 2, 2020 - Phase 2 STAR Study Encore Poster and Phase 3 Overview
Neurana Pharmaceuticals to Present at Solebury Trout Private Company Showcase
August 4, 2020 - Neurana to present at Solebury Trout Private Company Showcase on August 10th
Neurana Pharmaceuticals to Present at Upcoming Investor Conference
July 30, 2020 - Neurana to present at LifeSci Partners Summer Symposium on August 5th
Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study
June 8, 2020 - First patient has been enrolled in the Phase 1 central nervous effects (CNS) clinical study of tolperisone